Systemic therapy for melanoma: ASCO guideline update Q and A
VK Sondak, MB Atkins, H Messersmith… - JCO Oncology …, 2024 - ascopubs.org
Systemic Therapy for Melanoma: ASCO Guideline Update Q and A | JCO Oncology Practice
Skip to main content ASCO Publications Publications Journal of Clinical OncologyJCO Oncology …
Skip to main content ASCO Publications Publications Journal of Clinical OncologyJCO Oncology …
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease
JW Smithy, PB Chapman - The Cancer Journal, 2024 - journals.lww.com
The widespread adoption of immune checkpoint inhibitors and small molecule inhibitors of
the MAP kinase pathway has transformed the management of locally advanced and …
the MAP kinase pathway has transformed the management of locally advanced and …
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
GV Long, A Hauschild, M Santinami… - … England Journal of …, 2024 - Mass Medical Soc
Background The 5-year results of this trial showed that adjuvant therapy with dabrafenib
plus trametinib resulted in longer relapse-free survival and distant metastasis–free survival …
plus trametinib resulted in longer relapse-free survival and distant metastasis–free survival …
[PDF][PDF] XXIX Italian Melanoma Intergroup National Congress| 29 September-1 October 2023, Naples (Italy)
Italian Melanoma Intergroup - Dermatology Reports, 2024 - pagepress.org
Background: BRAF/MEK inhibitors have dramatically increased the response rate in
metastatic melanoma (MM) patients harboring BRAF mutation. However, several factors …
metastatic melanoma (MM) patients harboring BRAF mutation. However, several factors …